Valproic acid induces differentiation and transient tumor regression, but spares leukemia-initiating activity in mouse models of APL. (Q34254302)

31 July 2017

Valproic acid induces differentiation and transient tumor regression, but spares leukemia-initiating activity in mouse models of APL. (English)

1 reference

31 July 2017

1 reference

M Leiva

1

1 reference

31 July 2017

S Moretti

2

1 reference

31 July 2017

H Soilihi

3

1 reference

31 July 2017

I Pallavicini

4

1 reference

31 July 2017

L Peres

5

1 reference

31 July 2017

C Mercurio

6

1 reference

31 July 2017

R Dal Zuffo

7

1 reference

31 July 2017

S Minucci

8

1 reference

31 July 2017

H de Thé

9

1 reference

31 July 2017

15 February 2012

1 reference

31 July 2017

1 reference

31 July 2017

26

1 reference

31 July 2017

7

1 reference

31 July 2017

1630-1637

1 reference

https://scigraph.springernature.com/pub.10.1038/leu.2012.39

31 July 2017

0 references

cites work

Anticancer activities of histone deacetylase inhibitors

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.39

Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.39

Discovery of novel transcriptional and epigenetic targets in APL by global ChIP analyses: Emerging opportunity and challenge.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.39

Role of the histone deacetylase complex in acute promyelocytic leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.39

Fusion proteins of the retinoic acid receptor-alpha recruit histone deacetylase in promyelocytic leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.39

Acute promyelocytic leukemia: from highly fatal to highly curable

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.39

Acute promyelocytic leukaemia: novel insights into the mechanisms of cure

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.39

How I treat acute promyelocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.39

Leukemia with distinct phenotypes in transgenic mice expressing PML/RAR alpha, PLZF/RAR alpha or NPM/RAR alpha

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.39

Eradication of acute promyelocytic leukemia-initiating cells through PML-RARA degradation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.39

Revisiting the differentiation paradigm in acute promyelocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.39

Curing APL: differentiation or destruction?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.39

All-trans-retinoic acid in acute promyelocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.39

Relapse of acute promyelocytic leukemia with PML-RARalpha mutant subclones independent of proximate all-trans retinoic acid selection pressure

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.39

Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.39

Therapeutic targeting of transcription in acute promyelocytic leukemia by use of an inhibitor of histone deacetylase.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.39

Treatment of myelodysplastic syndromes with valproic acid alone or in combination with all-trans retinoic acid

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.39

Rational combinations using HDAC inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.39

A sumoylation site in PML/RARA is essential for leukemic transformation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.39

PLZF-RAR alpha fusion proteins generated from the variant t(11;17)(q23;q21) translocation in acute promyelocytic leukemia inhibit ligand-dependent transactivation of wild-type retinoic acid receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.39

The oncogenic capacity of HRX-ENL requires the transcriptional transactivation activity of ENL and the DNA binding motifs of HRX.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.39

A PMLRARalpha transgene initiates murine acute promyelocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.39

High-penetrance mouse model of acute promyelocytic leukemia with very low levels of PML-RARα expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.39

PML-RAR induces promyelocytic leukemias with high efficiency following retroviral gene transfer into purified murine hematopoietic progenitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.39

Retinoic acid and arsenic synergize to eradicate leukemic cells in a mouse model of acute promyelocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.39

Retinoic acid-induced apoptosis in leukemia cells is mediated by paracrine action of tumor-selective death ligand TRAIL.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.39

Mechanisms of selective anticancer action of histone deacetylase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.39

Identification of a myeloid committed progenitor as the cancer-initiating cell in acute promyelocytic leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.39

PML-RARalpha initiates leukemia by conferring properties of self-renewal to committed promyelocytic progenitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.39

The drug-induced degradation of oncoproteins: an unexpected Achilles' heel of cancer cells?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.39

Valproic acid stimulates proliferation and self-renewal of hematopoietic stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.39

Histone deacetylase inhibitor valproic acid enhances the cytokine-induced expansion of human hematopoietic stem cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.39

Effect of histone deacetylase inhibitor valproic acid on progenitor cells of acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.39

Opinion: how patients have benefited from mouse models of acute promyelocytic leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.39

In vivo analysis of the role of aberrant histone deacetylase recruitment and RAR alpha blockade in the pathogenesis of acute promyelocytic leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.39

The growth suppressor PML represses transcription by functionally and physically interacting with histone deacetylases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.39

PML regulates p53 acetylation and premature senescence induced by oncogenic Ras

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.39

Impairment of p53 acetylation, stability and function by an oncogenic transcription factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.39

Response to histone deacetylase inhibition of novel PML/RARalpha mutants detected in retinoic acid-resistant APL cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.39

Histone deacetylases and epigenetic therapies of hematological malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.39

Inhibitors of histone deacetylases induce tumor-selective apoptosis through activation of the death receptor pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.39

Tumor-selective action of HDAC inhibitors involves TRAIL induction in acute myeloid leukemia cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.39

RXR is an essential component of the oncogenic PML/RARA complex in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.39

inferred from DOI database lookup

7 January 2021

based on heuristic

The deacetylase inhibitor LAQ824 induces notch signalling in haematopoietic progenitor cells

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.39

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1038/LEU.2012.39

1 reference

Dimensions Publication ID

31 July 2017

0 references

1 reference